Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors

Rasmus Helgebostad 1, Mona-Elisabeth Revheim 1,2, Kjersti Johnsrud 1, Kristine Amlie 1, Abass Alavi 3 and James Patrick Connelly 1,4*

1 Division of Radiology and Nuclear Medicine, Oslo University Hospital, P.O. Box 4956 Nydalen, 0424 Oslo, Norway; helgebostad@gmail.com (R.H.); monar@ous-hf.no (M.-E.R.); kjohnsru@ous-hf.no (K.J.); kkrami@ous-hf.no (K.A.)
2 Institute of Clinical Medicine, University of Oslo, P.O. Box 1171 Blindern, 0318 Oslo, Norway
3 Department of Radiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA; abass.alavi@uphs.upenn.edu
* Correspondence: jamcon@OUS-hf.no

Abstract: Somatostatin receptor (SSTR) agonist tracers used in nuclear medicine scans are classically used for neuroendocrine tumor diagnosis and staging. SSTR are however, expressed more widely in a variety of cells as seen in the distribution of physiological tracer uptake during whole body scans. This provides opportunities for using these tracers for applications other than NETs and meningiomas. In this qualitative systematic review, novel diagnostics in SSTR-PET imaging are reviewed. A total of 70 studies comprised of 543 patients were qualitatively reviewed. Sarcoidosis, atherosclerosis and phosphaturic mesenchymal tumors represent the most studied applications currently with promising results. Other applications remain in progress where there are many case reports but a relative dearth of cohort studies. [18F]FDG PET provides the main comparative method in many cases but represents a well-established general PET technique that may be difficult to replace, without prospective clinical studies.

Keywords: somatostatin; PET; imaging; review; inflammation; benign; malignant; sarcoidosis; atherosclerosis; osteomalacia

1. Introduction

Somatostatin is a cyclic peptide hormone with two active forms consisting of either 14 or 28 amino acids regulating specific and selective functions depending on the location. Somatostatin-producing cells are typically neurons or endocrine-like cells found in high density in the central and peripheral nervous systems, the endocrine pancreas, liver, spleen and in the gut. They can also be found in smaller numbers in the thyroid, adrenals, submandibular glands, kidneys, prostate, placenta blood vessels, and immune cells [1].

Somatostatin bears several endocrine functions including pituitary regulation of growth hormone (GH) and thyroid stimulating hormone (TSH, inhibiting GH/TSH secretion through somatostatin secretion from the hypothalamus). Moreover, it has an inhibitory effect on various gastrointestinal functions, including gastric acid secretion, gastric emptying, intestinal motility, release of insulin and glucagon and various gastrointestinal hormones [2]. The peptide binds to the G-coupled receptor SSTR, one of a large class of cellular membrane receptor proteins with seven transmembrane segments containing a peptide binding region at the external surface and an internal signaling system based on G-proteins and changes in guanosine phosphorylation. The receptor acts as a switch that is activated by binding somatostatin. SSTR is expressed by nerve cells, many neuroendocrine cells and inflammatory cells such as lymphocytes, monocytes/macrophages, peripheral blood mononuclear cells and thymocytes [3]. There are five receptor subtypes SSTR1-5 expressed in different ratios in different organ systems. In the peripheral blood mononuclear
cells and in the spleen, mainly SSTR subtypes 2 and 3 are found; in the thymus, mainly SSTR subtypes 1, 2, and 3; in macrophages and dendritic cells, mainly SSTR subtype 2; in B lymphocytes, mainly SSTR subtype 3; and in T lymphocytes, SSTR subtypes 1 through 5 [4–7]. Receptor distribution is shown in Table 1.

Table 1. Distribution of somatostatin receptors in normal human tissue (adapted from [3–7]).

| Tissue          | Localization     | Receptor Subtype |
|-----------------|------------------|------------------|
| **Lymphatic:**  |                  |                  |
| Lymph nodes     | Germinal centers | SST2 (probable)  |
| Peyers Patches  | Germinal centers |                  |
| Solitary follicles (colon) | Germinal centers |                  |
| Appendix        | Germinal centers |                  |
| Spleen          | Red pulp         | SST2-3           |
| Thymus          | Medulla          | SST1-3           |
| **Immune cells:** |                  |                  |
| Macrophages     |                  | SST2             |
| Dendritic cells |                  | SST2             |
| B lymphocytes   |                  | SST3             |
| T lymphocytes   |                  | SST1-5           |
| **Kidneys:**    |                  |                  |
| Cortex          | Proximal tubules | SST2 (probable)  |
| Medulla         | Vasa recta       |                  |
| Prostate        | Smooth muscle    | SST2             |
| Thyroid gland   | Epithelial cells | SST2             |
| **GI-tract:**   |                  |                  |
| Stomach         |                  | SST1-4           |
| Small intestine |                  | SST1, SST5       |
| Liver           |                  | SST3             |
| Pancreas        |                  |                  |
| β cells         |                  | SST2             |
| α cells         |                  | SST3             |
| δ cells         |                  | SST5             |
| Adrenal glands  |                  | SST2             |
| Lung            |                  | SST4             |
| Heart           |                  | SST4             |

The SST receptor can be targeted with synthetic somatostatin analogues exhibiting both agonist and antagonist activity. Antagonist based tracers are not yet well established and are not included in this review. Octreotide was the first somatostatin agonist analogue developed for clinical application and is currently used in the treatment of neuroendocrine tumors. PET (positron emission tomography) tracers are created by binding octreotide (or analogue) with a metal radionuclide using a chelating agent such as DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid). This was achieved successfully with gallium-68 ([68Ga]) and copper-64 ([64Cu]) for PET use [5] in combination with DOTA-D-Phe-Tyr3-octreotide (DOTATOC), DOTA-1-Nal(3)-octreotide (DOTANOC), or DOTA-D-Phe-Tyr3-octreotate (DOTATATE), which differ mainly in their affinity to the various receptor subtypes (SSTR1-5). DOTATOC is more selective to type 2 and 5, DOTANOC 2,3 and 5, and DOTATATE type 2 [8]. Physiological uptake of [68Ga]Ga-DOTATOC is shown in Figure 1.
Somatostatin receptors (SSTR) tracers are routinely used in diagnostics and therapy of neuroendocrine tumors (NET) [5], particularly gastroenteropancreatic NETs. Meningiomas are non-neuroendocrine tumors that frequently exhibit a high level of SSTR 2 expression and are not infrequent incidental findings on SSTR-PET scans performed for NET diagnosis. As a result, literature continues to accumulate regarding the use of SSTR PET for meningioma diagnosis and treatment with this provides a good example of a non-NET application. There are already a number of reviews detailing this application, thus meningiomas are excluded from this review [10,11].

SSTRs are expressed in a multitude of cells around the body that could suggest other potential uses in PET imaging. In this review, we consider these commonly available SSTR-PET tracers in diagnostic uses other than NETs and meningiomas and present an overview of reported cases and applications.

2. Materials and Methods

A search was performed in PubMed (1993–February 2021) for the most common PET tracers in clinical use using keywords DOTATOC, DOTATATE and DOTANOC. Neuroendocrine tumors were excluded using the “NOT” command for keywords “neuroendocrine tumors”.

Figure 1. Physiological uptake of [68Ga]Ga-DOTATOC. An imaging protocol based on EANM guidelines was used [9]. A 145MBq bolus of [68Ga]Ga-DOTATOC was injected and imaging performed after 60 min.
roendocrine tumors were excluded using the “NOT” command for keywords “neuroendocrine” and “NET”. Pheochromocytoma and paraganglioma were considered as part of the neuroendocrine tumor group and excluded. As mentioned in the introduction, studies involving meningiomas were also excluded.

For this review we included observational cohort studies and case reports. Patients with indications other than NETs and meningiomas who had diagnostic radiolabeled somatostatin receptor analogue PET imaging, using DOTANOC, DOTATOC, DOTATATE tracers were included. Publications with emphasis on technical aspects related to generators, radiochemistry, animal models, experimental reports or physics were excluded. A flow diagram of the search process is shown in Figure 2.

Figure 2. Flow chart of the review process based on PRISMA methodology [12].
3. Results

Pubmed literature search yielded 768 results. The exclusion of non-English results and duplicates resulted in 760 articles. The titles/abstracts revealed 254 articles concerning NETs, 59 articles on meningiomas, 118 general articles about SSTR PET/CT without specific diagnostic focus, 83 articles regarding production and 134 involving therapeutic use. These articles were all excluded. A total of 112 full-text articles were assessed for eligibility. Using the same criteria, 43 full-text articles were excluded and 70 studies with a total of 543 patients were included in a qualitative systematic review. A PRISMA flow diagram [9] of the process is shown in Figure 2.

The literature can be grouped into two broad sections on inflammation including cardiovascular disease and ischemia, and neoplasia divided into benign and malignant tumors. An overview of the literature and references is given in Table 2. As can be expected for novel or incidental applications of SSTR tracers, the literature consists of relatively small cohort studies and a number of case reports. Tables 3 and 4 list details of cohort studies for each subject area. The case studies listed in Table 2 are reviewed in the Section 4.

SSTR tracer imaging protocols described in each study largely conform to standard protocols with regard to timing and activity used for neuroendocrine tumors [9]. Typically, a tracer activity of 75–300 MBq was administered and imaging performed 1 h (±30 min) after injection. Two exceptions are the study on disease activity in sarcoidosis by Sharma et al. [13] with activities of 1110–1480 MBq and the tumor-induced osteomalacia study by Breer et al. [14] with imaging performed 20 min after injection.

Table 2. Overview of pathology (other than NET and meningioma) yielded by the literature search.

| Inflammatory Disease | Cohort Studies (Table 3) | Case Reports |
|----------------------|-------------------------|-------------|
| Takayasu arteritis   | 1 ([15])                |             |
| Graves ophthalmopathy| 2 ([16,17])             |             |
| IgG mediated lymphadenopathy | 1 ([18]) |             |
| Endometriosis        | 1 ([19])                |             |
| Idiopathic pulmonary fibrosis | 1 ([20]) |             |
| Pulmonary tuberculosis| 1 ([21])               |             |
| Sarcoaidosis         |                         |             |
| • Thoracic           | 2 ([13,22])             |             |
| • Cardiac            | 4 ([23–26])             | 4 ([27–30]) |
| • Neural             | 1 ([31])                |             |
| Myocardial infarction associated inflammation | 2 ([32,33]) |             |
| Atherosclerosis      |                         |             |
| • Coronary and carotid | 1 ([34])              |             |
| • Aortic and carotid | 2 ([35,36])             |             |
| Ischemia in postoperative stroke | 1 ([37]) |             |

| Neoplasia            | Cohort Studies (Table 4) | Case Reports |
|----------------------|-------------------------|-------------|
| Benign               |                         |             |
| Phosphaturic mesenchymal tumors | 13 ([14,28–49]) | 17 ([50–66]) |
| Juvenile angiofibroma | 1 ([67])               |             |
| Enchondroma          | 1 ([68])                |             |
| Vertebral hemangioma | 1 ([69])                |             |
| Uterine leiomyoma    | 1 ([70])                |             |
| Malignant            |                         |             |
| Multiple myeloma     | 1 ([71])                | 1 ([72])    |
| Epithelioid hemangioendothelioma | 2 ([73,74]) |             |
| Renal clear cell carcinoma | 3 ([75–77]) |             |
| Gastrointestinal stromal tumor | 1 ([78]) |             |
| Hepatocellular carcinoma | 1 ([79])  |             |
| Choroidal melanoma   | 1 ([80])                |             |
| Osteosarcoma         | 1 ([81])                |             |
| Oligodendroglioma    | 1 ([82])                |             |
Table 3. Summary of cohort studies relating to inflammation (abbreviations: ([18]F)FDG, 2-deoxy-2-[18]F]fluoro-D-glucose, Pt, number of patients).

| Author            | Ref  | Type of Study | Pt | Radiotracer Scanner, Injected Activity and Delay before Acquisition | Comments                                                                 |
|-------------------|------|---------------|----|---------------------------------------------------------------------|--------------------------------------------------------------------------|
| **Endometriosis** |      |               |    |                                                                     |                                                                          |
| Fastrez, M. (2017)| [19] | Pilot study 12 | 12 | [(68)Ga]Ga-DOTA-TATE PET/CT 2 MBq/kg, 60 min                       | DOTATATE showed uptake in rectovaginal deep infiltrating endometriosis and adenomyoma, but not in superficial peritoneal endometriosis or ovarian endometrioma. Immunohistochemistry used to confirm findings. |
| **Idiopathic pulmonary fibrosis** | | | | | |
| Ambrosini, V. (2010)| [20] | Prospective 14 | 14 | [(68)Ga]Ga-DOTA-NOC PET/CT (GE discovery STE) 120–180 MBq, 60 min | DOTANOC uptake corresponded to areas of HRCT anomalies in patients with idiopathic pulmonary fibrosis, suggesting SSTR expression. |
| **Pulmonary tuberculosis** | | | | | |
| Naftalin, C. (2020)| [21] | Prospective 14 | 14 | [(68)Ga]Ga-DOTA-NOC, PET/MR (Siemens biograph mMR) 191.7 ± 9.3 MBq, dynamic uptake image analysis on data after 60 min [(18]F]FDG | DOTANOC able to detect pulmonary tuberculosis lesions, but [(18]F]FDG was more sensitive for both active and sub-clinical lesions. |
| **Systemic sarcoidosis** | | | | | |
| Sharma, S. (2018)| [13] | Prospective 39 | 39 | [(68)Ga]Ga-DOTA-NOC PET/CT (Siemens biograph mCT) 1110–1480 MBq, 30 min | 27/39 patients symptomatic sarcoidosis with thoracic involvement, increased DOTANOC uptake in 25/27. |
| Nobashi, T. (2016)| [22] | Prospective 20 | 20 | [(68)Ga]Ga-DOTA-TOC PET/CT (GE Discovery STE) 119.7 ± 29.3 MBq, 67.5 ± 8.5 min | SSTR PET positive in 19 patients, 67Ga-scintigraphy in 17. Suggests SSTR PET is superior in detecting sarcoidosis lesions. |
| **Cardiac sarcoidosis** | | | | | |
| Bravo, P. (2021)| [23] | Pilot study 13 | 13 | [(68)Ga]Ga-DOTA-TATE, PET/CT (GE Discovery RX or Lightspeed VCT 64) 2 MBq/kg, 60 min [(18]F]FDG PET/CT | DOTATATE imaging less sensitive than [(18]F]FDG for detection of myocardial inflammation. |
| Gormsen, L. (2016)| [24] | Prospective 19 | 19 | [(68)Ga]Ga-DOTA-NOC PET/CT(Siemens Biograph 64), 3 MBq/kg, 90 min [(18]F]FDG, | Large proportion of [(18]F]FDG-PET images were inconclusive, better diagnostic accuracy with DOTANOC in known/suspected cardiac sarcoidosis. |
| Pizarro, C. (2018)| [25] | Prospective 17 | 17 | [(68)Ga]Ga-DOTA-TOC PET/CT(Siemens Biograph 2) 2 MBq/kg, 65 ± 28 min | Reported SSTR PET allowed for visualization of acute cardiac sarcoidosis and absent uptake correlated with use of immunosuppressants. SSTR PET may be useful in treatment response. |
| Lapa, C. (2016)| [26] | Prospective 15 | 15 | [(68)Ga]Ga-DOTA-NOC PET/CT (Siemens Biograph 2 or mCT 64) 124 ± 31 MBq, 60 min | SSTR PET in high concordance with cardiac MRI, in patients with systemic sarcoidosis and myocardial involvement. |
### Table 3. Cont.

| Author                | Ref | Type of Study | Pt | Radiotracer Scanner, Injected Activity and Delay before Acquisition | Comments                                                                                                                                                                                                 |
|-----------------------|-----|---------------|----|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **Myocardial infarction associated inflammation**                                                                                                                                  |
| Tarkin, J. (2019)     | [32] | Prospective   | 12 | \[^{68}\text{Ga}]\text{Ga-DOTA-TATE As for Tarkin (2017) [34]}       | DOTATATE imaging detects myocardial inflammation post infarction, both in old and ischemic injury, possibly providing a biomarker for inflammation in heart failure.                                           |
| Lapa, C. (2015)       | [33] | Prospective   | 12 | \[^{68}\text{Ga}]\text{Ga-DOTA-TOC PET/CT (Siemens Biograph mCT 64), 104 ± 30 MBq, 60 min} | DOTATOC correlates with cardiac MRI when detecting myocardial infarction, less specific with myocarditis.                                                                                                    |
| **Atherosclerosis**                                                                                                                                                                 |
| Tarkin, J. (2017)     | [34] | Prospective   | 42 | \[^{68}\text{Ga}]\text{Ga-DOTA-TATE PET/CT (GE Discovery 690), 147.8 ± 31.6 MBq, dynamic up to 90 min or static after 60 min [\[^{18}\text{F}]\text{FDG}} | DOTATATE provides quantifiable, cell-specific marker of atherosclerotic inflammation that outperforms \[^{18}\text{F}]\text{FDG in coronary arteries.}                              |
| Lee, R. (2018)        | [35] | Retrospective | 50 | \[^{68}\text{Ga}]\text{Ga-DOTA-TOC PET/CT (Siemens Biograph mCT 40 or 64), 185 MBq, 60 min} | DOTATOC findings in thoracic aorta correlates significantly with cardiovascular risk factors.                                                                                                               |
| Pedersen, S. (2015)   | [36] | Prospective   | 10 | \[^{64}\text{Cu}]\text{Cu-DOTA-TATE PET/MR (Siemens Biograph mMR), 154 MBq, 85 & 299 min} | DOTATATE accumulates in atherosclerotic plaques of the carotid artery. Potential for identifying vulnerable plaques.                                                                                      |

### Table 4. Summary of cohort studies relating to neoplasia (abbreviations: \[^{18}\text{F}]\text{FDG, 2-deoxy-2-[\[^{18}\text{F}]\text{fluoro-D-glucose; [\[^{111}\text{In}]\text{In OCT, Indium pentetreotide; Pt, number of patients).}}}

| Author                | Ref | Type of Study | Pt | Radiotracer Scanner, Injected Activity and Delay before Acquisition | Comments                                                                                                                                                                                                 |
|-----------------------|-----|---------------|----|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **Phosphaturic mesenchymal tumors (PMT)**                                                                                                                                          |
| John, J. (2019)       | [38] | Retrospective | 16 | \[^{68}\text{Ga}]\text{Ga-DOTA-TATE PET/CT (Siemens Biograph), 75–185 MBq, 30–45 min} | Out of 16 patients with clinically suspected oncogenic osteomalacia 13 patients were found to be SSTR PET positive for a possible mesenchymal tumour. 10 patients underwent surgery, all of which biopsy confirmed PMT. |
| Paquet, M. (2018)     | [40] | Prospective   | 15 | \[^{68}\text{Ga}]\text{Ga-DOTA-TOC PET/CT (Siemens Biograph mCT, Phillips GeminiTF16), 1.6 MBq/kg, 60 min.} | 9/15 identified suspect tumor, 8 removed surgically, all of them histologically proven to be PMT.                                                                                                      |
| Singh, D. (2017)      | [49] | Prospective   | 17 | \[^{68}\text{Ga}]\text{Ga-DOTA-NOC PET/CT (Siemens mCT biograph 64), 111–148 MBq, 45 ± 15 min.} | DOTANOC PET/CT revealed 52 lesions in 17 patients with elevated FGF-23 and hypophosphatemia, where 11 were highly suspicious for culprit lesions. Subsequent anatomical imaging with CT/MRI showed concordant results in 7 out of 9 patients. These lesions were excised and histologically verified PMTs. Multiple lesions make it difficult to identify the culprit lesion. |
### Table 4. Cont.

| Author                  | Ref   | Type of Study | Pt | Radiotracer Scanner, Injected Activity and Delay before Acquisition | Comments                                                                                                                                 |
|-------------------------|-------|---------------|----|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| Satyaraddi, A. (2017)   | [41]  | Retrospective | 13 | \[^{68}\text{Ga}]\text{Ga-DOTA-TATE,}[^{18}\text{F}]\text{FDG Scan details not given,} | DOTATATE revealed PMT in 9/9 patients, of whom 3 declined surgery. Other 6 had histologically verified PMTs.                                     |
| González, G. (2017)     | [42]  | Retrospective | 6  | \[^{68}\text{Ga}]\text{Ga-DOTA-TATE Scan details not given} | Two tumors located using DOTATATE                                                                                                                                                                   |
| El-Maouche, D. (2016)   | [43]  | Prospective   | 11 | \[^{68}\text{Ga}]\text{Ga-DOTA-TATE PET/CT(Siemens mCT), ca 185 MBq, 60 min}[^{111}\text{In}][\text{In-OCT,}[^{18}\text{F}]\text{FDG} | 6/11 patients had tumor successfully identified. DOTATATE identified 6/6,[^{111}\text{In}][\text{In-OCT} and[^{18}\text{F}]\text{FDG both with 4/6.} |
| Bhavani, N. (2016)      | [44]  | Retrospective | 10 | \[^{68}\text{Ga}]\text{Ga-DOTA-NOC PET/CT (GE Discovery 609) 111–185 MBq, 60 min} | DOTANOC detected PMT in 9/10 cases. 6/10 made full clinical recovery after complete resection.                                                                                                       |
| Zhang, J. (2015)        | [45]  | Retrospective | 54 | \[^{68}\text{Ga}]\text{Ga-DOTA-TATE PET/CT(Siemens Biograph 64) 111–148 MBq, 60 min} | DOTATATE positive in 44 patients, where 33 had surgery to remove lesions. 32 histologically confirmed PMT. 10 who were not positive responded well to conservative treatment and thus PMT can be ruled out. |
| Agrawal, K. (2015)      | [46]  | Retrospective | 6  | \[^{68}\text{Ga}]\text{Ga-DOTA-TATE PET/CT(GE Discovery STE-16) 1.5 MBq/kg, 45–60 min,}[^{18}\text{F}]\text{FDG} | [^{18}\text{F}]\text{FDG-PET identified PMT in 2/4 patients. DOTATATE identified PMT in 5/6 patients.}                                                                                              |
| Jadhav, S. (2014)       | [47]  | Retrospective | 16 | \[^{68}\text{Ga}]\text{Ga-DOTA-TATE PET/CT (Discovery STE) 74–111 MBq, 60–90 min.}[^{18}\text{F}]\text{FDG,}[^{99}\text{Tc}]\text{Tc-HYNIC-TOC} | 9/16 patients had tumor successfully identified. DOTATATE, HYNIC-TOC (tectrotyd) both identified 7/7,[^{18}\text{F}]\text{FDG 4/8.} |
| Breer, S. (2014)        | [14]  | Prospective   | 5  | \[^{68}\text{Ga}]\text{Ga-DOTA-TATE PET/CT(Siemens Biograph), 58–110 MBq, 20 min,}[^{111}\text{In}][\text{In-OCT} | [^{111}\text{In}][\text{In-OCT SPECT-CT identified 1/5 tumors, DOTATATE-PET 5/5. Histologically confirmed PMT.}}                                                                 |
| Clifton-Bligh, R. (2013) | [48]  | Prospective   | 6  | \[^{68}\text{Ga}]\text{Ga-DOTA-TATE PET/CT, 103–226 MBq, 45–60 min} | DOTATATE detected PMT in all 6 cases. 5/6 made full clinical recovery after resection. Patient with symptoms with residual on follow up PET.                                                             |

**Juvenile angiofibroma**

| Author                  | Ref   | Type of Study | Pt | Radiotracer Scanner, Injected Activity and Delay before Acquisition | Comments                                                                                                                                 |
|-------------------------|-------|---------------|----|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| Gronkiewicz, Z. (2016)  | [67]  | Prospective   | 6  | \[^{68}\text{Ga}]\text{Ga-DOTA-TATE PET/CT (Siemens Biograph 64) 120–160 MBq, 60 min} | DOTATATE showed uptake in areas matching the pathologic tissue in juvenile angiofibroma.                                                                                                       |

**Multiple myeloma**

| Author                  | Ref   | Type of Study | Pt | Radiotracer Scanner, Injected Activity and Delay before Acquisition | Comments                                                                                                                                 |
|-------------------------|-------|---------------|----|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| Sonmezoglu, K. (2017)   | [71]  | Prospective   | 21 | \[^{68}\text{Ga}]\text{Ga-DOTA-TATE PET/CT (Siemens Biograph 6 or GE Discovery V710), 100–150 MBq, 45–60 min.}[^{18}\text{F}]\text{FDG} | No significant difference was found between the two modalities in terms of lesion numbers detected in multiple myeloma. However, diffuse bone marrow uptake of DOTATATE seems to be a predicting factor for overall survival. |

4. Discussion

4.1. Inflammation

Activated macrophages were shown to express a large amount of SSTR2 making these a possible target for SSTR PET in inflammatory disease. Historically, inflammatory cells’ requirement for glucose has been the primary target for PET/CT with the glucose analog 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG). This method has limitations in tissues with high glucose consumption such as the brain and heart, or in tissue with high background tracer uptake such as the kidneys. The papers in this section considered the utility of SSTR PET for investigating inflammation and in many cases compared the results with [18F]FDG PET.

4.1.1. Diverse Inflammatory Processes

Two cases of Takayasu arteritis (TA) were reported by Tarkin et al. [15] where [18F]FDG PET proved useful in diagnosing TA but more limited in value for tracking therapeutic responses or detecting residual arteritis. SSTR PET/MRI accurately identified the lesions in both cases suggesting potential for further evaluation. Broadly speaking [18F]FDG is highly sensitive but relatively non-specific, and cannot accurately distinguish arteritis from metabolically active vascular remodeling [83]. SSTR tracers may provide an alternative. Arora et al. [16] reported two cases of Graves orbitopathy where SSTR PET/CT identified lesions without physiological uptake in adjacent muscle tissue, suggesting higher sensitivity than [18F]FDG PET. Pichler et al. [17] showed similar findings in one patient. Cheng et al. [18] reported a case where SSTR PET/CT incidentally revealed IgG4 mediated lymphadenopathy in a 60 year old male, confirmed on histology.

In an observational study of 14 patients with idiopathic pulmonary fibrosis Ambrosini et al. [20] reported SSTR tracer uptake directly corresponded to pathological areas on high-resolution CT (HRCT). A control group of nonspecific interstitial pneumonia showed faint tracer uptake and healthy individuals showed no uptake.

Fastrez et al. [19] conducted a pilot study of 12 patients with various degrees of endometriosis. SSTR PET/CT showed uptake in rectovaginal deep infiltrating endometriosis and adenomyoma, but not in superficial peritoneal endometriosis or ovarian endometrioma. The study concluded that SSTR PET cannot be used to diagnose endometriosis.

SSTR tracer and [18F]FDG PET/MRI imaging were compared in 14 patients with pulmonary tuberculosis by Naftalin et al. [21]. [68Ga]Ga-DOTANOC was able to detect pulmonary lesions, but [18F]FDG was more sensitive for both active and subclinical lesions (see Figure 3).

In summary, these papers suggest that SSTR-PET tracers show uptake in diverse inflammatory processes, in some cases outperforming [18F]FDG PET regarding sensitivity and specificity. However, SSTR PET is generally less applicable than [18F]FDG, performing less well in tuberculosis and endometriosis. Tissue receptor diversity may underlie this variability.

4.1.2. Sarcoidosis

Sarcoidosis is a heterogeneous, granulomatous disorder of unknown etiology. In the past, gallium-67 [67Ga]citrate scintigraphy was used for sarcoidosis but bears lower resolution/sensitivity and higher patient dose than PET and has been superseded by conventional radiology and [18F]FDG PET. Guidelines from European and American nuclear medicine and cardiac societies recommend the use of [18F]FDG PET in cardiac sarcoidosis diagnosis [84]. As few as 5% of patients with systemic sarcoidosis have clinical cardiac sarcoidosis, but autopsy studies reveal that as many as 70% have subclinical cardiac involvement. [18F]FDG PET otherwise plays a role in patients investigated for fever of unknown origin or lymphadenopathy where the eventual diagnosis is sarcoidosis.
In 11 studies with a total of 130 patients, SSTR PET was investigated as an alternative to $^{18}$F-FDG in systemic sarcoidosis. Sharma et al. [13] investigated 39 patients with sarcoidosis of whom 27 had symptomatic sarcoidosis with thoracic involvement, where $[^{68}\text{Ga}]\text{Ga-DOTANOC}$ uptake indicated increased disease activity in 25/27 patients (92%). In the asymptomatic group, 2/12 exhibited increased disease activity on $[^{68}\text{Ga}]\text{Ga-DOTANOC}$ PET. Nobashi et al. [22] compared $[^{68}\text{Ga}]\text{Ga-DOTATOC}$ PET to $[^{67}\text{Ga}]$citrate scintigraphy (which is taken up in sarcoid lesions by mechanisms other than somatostatin receptors) in 20 patients. $[^{68}\text{Ga}]\text{Ga-DOTATOC}$ was positive in 19/20 patients vs. 17/20 in scintigraphy and demonstrated more lesions, suggesting SSTR PET is better at identifying sarcoid lesions; however, this can be explained by PET’s superior sensitivity compared to scintigraphy and not necessarily by higher lesion uptake.

A total of eight studies consider SSTR tracers specifically for cardiac sarcoid. Bravo et al. [23] reported a pilot study with 13 patients and found SSTR PET less sensitive than $[^{18}\text{F}]\text{FDG}$ PET for detection of myocardial inflammation. Some representative results are shown in Figure 4.

In contrast Gormsen et al. [24] compared $[^{68}\text{Ga}]\text{Ga-DOTANOC}$ to $[^{18}\text{F}]\text{FDG}$ and showed a large proportion of $[^{18}\text{F}]\text{FDG}$ images were inconclusive whereas $[^{68}\text{Ga}]\text{Ga-DOTANOC}$ imaging illustrated excellent diagnostic accuracy, although with significant inter-observer variability. Pizarro et al. [25] reported 17 patients with cardiac sarcoid and varying degrees of immunosuppressant treatment imaged using SSTR PET and cardiac MR. They concluded SSTR PET may be more specific for acute inflammation and bear a potential role in treatment response. Other earlier or smaller studies demonstrated similar or improved performance of SSTR-PET tracers compared with $[^{18}\text{F}]\text{FDG}$ [26–30]. A case of neurosarcoidosis imaged with $[^{68}\text{Ga}]\text{Ga-DOTATATE}$ was reported by Unterrainer et al. [31].
Figure 4. Patient with thoracic sarcoidosis. Both FDG and DOTATE PET images show extensive lymphadenopathy and cardiac inflammation (arrow on maximum intensity projections A,D) Axial CT (B,E) and fused PET-CT (C,F). Reprinted with permission from ref. [23] Copyright 2019 American Society of Nuclear Cardiology.

These studies show variable comparative sensitivity of SSTR-PET tracers compared to $[^{18}\text{F}]$FDG PET. One factor mentioned is the reliability of the $[^{18}\text{F}]$FDG PET heart protocol that includes patients undertaking a low carbohydrate diet for 24–48 h, fasting for 12 h or more prior to imaging and a heparin bolus. This complicates the logistics of the procedure, adds the risk of poor compliance and may be a factor in differences in sensitivity of the studies. SSTR-PET tracers do not require a similar heart protocol.

4.1.3. Other Causes of Myocardial Inflammation

Tarkin et al. [32] studied 12 patients with a history of myocardial infarction (MI) comparing $[^{68}\text{Ga}]$Ga-DOTATATE to $[^{18}\text{F}]$FDG PET within infarcted and non-infarcted segments. $[^{68}\text{Ga}]$Ga-DOTATATE exhibited very low background myocardial binding; however, myocardial $[^{18}\text{F}]$FDG was uninterpretable in five scans (42%) despite pre-scan fasting. $[^{68}\text{Ga}]$Ga-DOTATATE imaging detected post infarction myocardial inflammation in both old and new ischemic injury. Close correlation between SSTR PET and MR in 12 patients with active peri/myocarditis or subacute myocardial infarction was reported by Lapa et al. [33]. Both studies suggest SSTR PET may have potential as a biomarker for cardiac remodeling.

4.1.4. Atherosclerosis

Vulnerable plaques can be identified with SSTR-analogs by uptake in activated macrophages. There were three studies in this category. Lee, et al. [35] retrospectively investigated 50 patients originally screened with SSTR PET for NETs to observe whether there was incidental uptake in the thoracic aorta and found uptake correlating with cardiovascular risk factors, suggesting potential for imaging vulnerable plaque. Tarkin et al. [34] compared $[^{68}\text{Ga}]$Ga-DOTATATE with $[^{18}\text{F}]$FDG in coronary, carotid and aortic artery plaque in 42 patients. Both tracers distinguish culprit from non-culprit plaque in coronary and carotid arteries in patients with acute coronary syndrome (ACS), stroke, or transient ischemic attack (TIA); however, nearby background $[^{18}\text{F}]$FDG uptake rendered coronary $[^{18}\text{F}]$FDG scans uninterpretable in a significant number of patients (64%). $[^{68}\text{Ga}]$Ga-DOTATATE scans were readable in all patients and supported the view that SSTR PET offers superior
coronary imaging, excellent macrophage specificity and better power in discriminating high-risk versus low-risk coronary lesions. Both the study by Tarkin et al. [34] and a study by Pedersen et al. [36] use histopathological methods to correlate SSTR tracer uptake with SSTR2, CD (cluster of differentiation) 68 and CD163 expression in activated macrophages.

In summary, in coronary and vascular disease, SSTR PET shows some tracer uptake associated with active macrophages in inflammatory lesions, both acute and chronic, and contains a distinct advantage over $^{18}$F-FDG PET with much lower background uptake.

4.1.5. Neuroinflammation

Dundar et al. [37] report three cases of incidentally detected stroke in oncology scans using $^{68}$Ga-DOTATATE, $^{11}$C-choline and $^{18}$F-FDG tracers suggesting tracer uptake in neuroinflammation in regions of acute/subacute stroke.

4.2. Benign Neoplasia

Neuroendocrine tumors originate from a cell population normally expressing SSTRs and the well differentiated types of tumor typically overexpress these receptors. Several other neoplastic processes were found to exhibit increased expression of SSTRs as well. The reason is not fully understood, but is most likely linked to the role of somatostatin in regulating proliferation, mitogenesis and apoptosis [6]. A total of 46 studies were found investigating neoplastic processes other than NETs, consisting of a few exceptions with reports of incidental findings and small case studies.

4.2.1. Tumor-Induced Osteomalacia and Phosphaturic Mesenchymal Tumors

Tumor-induced osteomalacia (TIO), also termed oncogenic osteomalacia, is a paraneoplastic syndrome typically caused by small benign mesenchymal tumors and characterized by hypophosphatemia (phosphaturic mesenchymal tumors, PMT). Tumor cells produce fibroblast growth factor 23 (FGF23) which in turn decreases proximal tubule reabsorption of phosphates and also inhibits vitamin D3 metabolism. This mobilizes calcium and phosphate from bones, and reduces osteoblastic activity which leads to bone tissue loss. It is diagnosed by identifying chronic hypophosphatemia, elevated FGF23 and decreased 1,25-OH2-Vitamin D [85]. Complete removal of the tumor is curative, which highlights the importance of locating the tumor. SSTRs were found on the cell membranes of active FGF23 secreting tumors with variable degrees of expression and thus SSTR analog tracers could be helpful in imaging [86]. A total of 30 studies involving 196 patients investigated TIO with SSTR PET. Single case studies comprised 16 of 30 reports, as can be expected with such a rare disease.

Zhang [45] retrospectively reviewed 54 patient histories with clinically suspected TIO. SSTR PET/CT was positive in 44 patients, among which 33 underwent surgery to remove lesions. Postsurgical pathological examination confirmed causative tumors in 32 patients whose symptoms diminished after surgery. El-Maouche et al. [43] performed a prospective study of 11 patients comparing $^{68}$Ga-DOTATATE with $^{18}$F-FDG and $^{111}$In-pentetreotide (octreoscan). Six patients had a culprit tumor successfully identified. $^{68}$Ga-DOTATATE detected 6/6, $^{18}$F-FDG and octreoscan both found 4/6 suggesting $^{68}$Ga-DOTATATE exhibited better sensitivity than the alternatives. Small studies by Agrawal et al. [46] and Jadhav et al. [47] also reported higher sensitivity and specificity for SSTR tracers compared with $^{18}$F-FDG. Multiple other case and small studies summarized in Table 2 report localization of culprit lesions in patients with TIO using SSTR tracers [14,38–42,44,48–66]. An example showing culprit lesions identified in 3 patients using $^{68}$Ga-DOTATATE PET-CT from a small study by John et al. [38] is shown in Figure 5.
In summary, PMT is a rare lesion that can arise in the head and neck or lower extremities. PET is typically performed as a whole body protocol (+/− extremities) and therefore lends itself to uncovering primary lesions of unknown origin. The data suggest that SSTR tracers outperform [18F]FDG and is slowly becoming accepted as a sensitive imaging method for localizing the culprit lesion [87].

4.2.2. Other Benign Tumors

Juvenile angiofibroma presents with rapidly growing vessels, associated with a higher SSTR2A expression in patients. Gronkiewicz et al. [67] performed a prospective study in six patients using SSTR PET that showed weak uptake in areas matching the pathologic tissue. In all cases, immunohistochemical examination revealed SSTR2A with a high staining index. The weak uptake was suggested to be due to intracellular localization of receptors.

A case of an incidental enchondroma in the right tibia was reported by Mahajan et al. [68] imaged on SSTR PET suggesting overexpression of SSTR in enchondromas. Vertenten et al. [69] described a case of a patient with known pancreatic cancer showing [68Ga]Ga-DOTATATE uptake in the spine suspected to be metastases. CT showed characteristic appearances of multiple hemangiomas.

Liu et al. [70] described a case where [68Ga]Ga-DOTATATE uptake was observed in an incidentally detected uterine leiomyoma.

These benign incidental findings with SSTR tracer uptake highlights the potential for false positive findings on SSTR-PET scans performed for NETs.

4.3. Malignant Disease

4.3.1. Multiple Myeloma (MM)

Multiple myeloma (MM) is a neoplasm of plasma B cells characterized by bone marrow infiltration with an overproduction of a monoclonal plasma cell population and antibodies, often leading to skeletal lesions, hypercalcemia and kidney dysfunction [88]. Sharma et al. [72] described a patient with MM with two osteolytic lesions demonstrating high tracer uptake on SSTR PET/CT. Sonmezoglu et al. [71] reported a prospective study of 21 patients with known MM where all patients were scanned with both [18F]FDG PET/CT and [68Ga]Ga-DOTATATE PET/CT. No significant difference was found between the two modalities in terms of lesion numbers detected. However, diffuse bone marrow uptake of [68Ga]Ga-DOTATATE seemed to be a predictive factor for reduced overall survival. Some
lesions visible on $^{18}$F-FDG were not detected on SSTR PET and the authors hypothesized that this might be influenced by a mismatch between receptor expression and tracer-binding affinity, particularly for SSTR3 and 5 receptors.

4.3.2. Epithelioid Hemangioendothelioma (EHE)

Epithelioid hemangioendothelioma (EHE) is a rare low-grade tumor originating from vascular endothelial or pre-endothelial cells with the potential to metastasize and recur [89]. Derlin et al. [74] described a case where $^{68}$Ga-DOTATATE and $^{18}$F-FDG identified vertebral metastasis from EHE. $^{68}$Ga-DOTATATE demonstrated a higher tumor to background ratio. Long et al. [73] reported a case of EGE in the right upper mediastinum located with $^{68}$Ga-DOTATATE, pathologically confirmed after resection. This case was also associated with TIO (see Section 4.2.1). A recent consensus statement on EHE diagnosis and treatment [89] mentions $^{18}$F-FDG PET as a useful adjunct. However, it remains yet to be established whether SSTR PET represents a better option.

4.3.3. Renal Cell Carcinoma Metastases

Vamadevan et al. [75] reported a case where metastasis from clear cell renal cell carcinoma (ccRCC) in the pancreas was incidentally detected on SSTR PET/CT. Vamadevan et al. [76] subsequently continued to report progression and a metastasis in the patient’s left thigh. Höög et al. [77] retrospectively compared $^{68}$Ga-DOTATOC in one patient vs. $^{18}$F-FDG in another patient, both diagnosed with ccRCC and with lesions suspicious for metastases. $^{18}$F-FDG showed no uptake in an adrenal metastasis. $^{68}$Ga-DOTATOC identified a pancreatic metastasis. Both lesions were histopathologically proven to be of ccRCC origin and to demonstrate SSTR2 expression. These case reports highlight both the potential utility of SSTR tracers for RCC metastases but also the need to consider differential diagnoses on SSTR scans performed for neuroendocrine tumors.

4.3.4. Various Malignancies Reported as Case Reports

Braat et al. [78] reported of a case where SSTR PET detected a gastrointestinal stromal tumor (GIST) in the appendix. Savelli et al. [82] reported a case where SSTR PET detected relapse of a previously resected oligodendroglioma. The article suggested the consideration of further research in theragnostics based on the significant tracer uptake and contrast and potential for peptide receptor radionuclide therapy (PRRT). Freesmeyer et al. [79] reported a case where SSTR PET incidentally detected a hepatocellular carcinoma (HCC) with skeletal metastasis. Shamim et al. [80] reported a case where SSTR PET incidentally detected metastasis from choroidal melanoma in the pancreas. Qin et al. [81] compared $^{68}$Ga-DOTATATE and $^{18}$F-FDG uptake in osseous lesions from synchronous multifocal osteosarcoma. $^{18}$F-FDG did not identify lesions; however, $^{68}$Ga-DOTATATE accumulated in lesions which were later resected and pathologically confirmed.

In summary, these studies and cases highlight that SSTR tracers provide a potential alternative to $^{18}$F-FDG for imaging certain malignancies other than NET. In NET tumors, $^{18}$F-FDG and SSTR tracers are often complementary in their avidity for tumor types, reflecting the degree of differentiation and proliferation and this observation appears to apply to other tumor types. $^{18}$F-FDG however, is a well-established and accessible technique with relatively well understood kinetics and metabolism whereas SSTR tracers can bear potentially great specificity but are dependent on SSTR expression, which is often much less well understood in many lesion types.

5. Conclusions

SSTR tracers bear applications beyond its classical use in neuroendocrine tumors and meningiomas. Numerous tissues express SSTR1-5 and pathological processes originating from these tissues can provide targets for SSTR imaging. Use of SSTR PET for investigating tumor-induced osteomalacia and localization of culprit lesions is virtually an established technique.
Inflammation, particularly associated with sarcoidosis and atherosclerosis, represents another application with promising results. Activated macrophages express SSTR and take up SSTR tracers which may provide a level of specificity not available with $^{18}$F-FDG PET. In addition, SSTR tracers exhibit advantageously low background uptake in the heart, brain and arterial wall compared with $^{18}$F-FDG.

Other applications remain a work in progress, where there exist many case reports but a relative dearth of cohort studies. $^{18}$F-FDG PET provides the established comparative PET method in many cases, and frequently shows different sensitivity reflecting the different underlying physiology and uptake mechanism. In analogy to NET, SSTR PET can be performed as a complementary PET technique to $^{18}$F-FDG PET, particularly where the lesion is likely to be well differentiated and/or express SSTR receptors.

Moreover, new applications for SSTR tracers bear the advantage of potentially novel theragnostic opportunities for treatment with SSTR-based peptide receptor radionuclide therapy (PRRT).

**Author Contributions:** Conceptualization, R.H., J.P.C. and M.-E.R.; methodology, R.H., J.P.C. and M.-E.R.; validation, J.P.C., M.-E.R., K.J. and A.A.; investigation, R.H. and J.P.C.; resources, R.H. and M.-E.R.; writing—original draft preparation, R.H.; writing—review and editing, J.P.C., M.-E.R., K.J., K.A. and A.A.; supervision, J.P.C. and M.-E.R.; project administration, M.-E.R. and J.P.C. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Patient consent was given for use of the image in Figure 1.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Patel, Y.C.; Reichlin, S. Somatostatin in Hypothalamus, Extrahypothalamic Brain, and Peripheral Tissues of the Rat. *Endocrinology* **1978**, *102*, 523–530. [CrossRef]

2. Ando, H. Chapter 5-Somatostatin. In *Handbook of Hormones*; Takei, Y., Ando, H., Tsutsui, K., Eds.; Academic Press: San Diego, CA, USA, 2016; p. 36-e5.

3. Narayanan, S.; Kunz, P.L. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. *J. Natl. Compr. Cancer Netw.* **2015**, *13*, 109–117. [CrossRef]

4. Bhanat, E.; Koch, C.A.; Parmar, R.; Garla, V.; Vijayakumar, V. Somatostatin Receptor Expression in Non-Classical Locations—Clinical Relevance? *Rev. Endocr. Metab. Disord.* **2018**, *19*, 123–132. [CrossRef]

5. Pauwels, E.; Cleeren, F.; Bormans, G.; Deroose, C.M. Somatostatin Receptor PET Ligands—The Next Generation for Clinical Practice. *Am. J. Nucl. Med. Mol. Imaging* **2018**, *8*, 311–331. [PubMed]

6. Volante, M.; Bozzalla-Cassione, F.; Papotti, M. Somatostatin Receptors and Their Interest in Diagnostic Pathology. *Endocr. Pathol.* **2004**, *15*, 275–292. [CrossRef]

7. Reubi, J.C.; Schaer, J.C.; Markwalder, R.; Waser, B.; Horisberger, U.; Laissue, J. Distribution of Somatostatin Receptors in Normal and Neoplastic Human Tissues: Recent Advances and Potential Relevance. *Yale J. Biol. Med.* **1998**, *70*, 471–479.

8. Cascini, G.L.; Cuccurullo, V.; Tamburini, O.; Rotondo, A.; Mansi, L. Peptide Imaging with Somatostatin Analogues: More than Cancer Probes. *Curr. Radiopharm.* **2013**, *6*, 36–40. [CrossRef] [PubMed]

9. Bozkurt, M.F.; Virgolini, I.; Balogova, S.; Beheshti, M.; Rubello, D.; Decristoforo, C.; Ambrosini, V.; Kjaer, A.; Delgado-Bolton, R.; Kunikowska, J.; et al. Guideline for PET/CT Imaging of Neuroendocrine Neoplasms with $^{68}$Ga-DOTA-Conjugated Somatostatin Receptor Targeting Peptides and $^{18}$F-DOPA. *Eur. J. Nucl. Med. Mol. Imaging* **2017**, *44*, 1588–1601, Erratum in *Eur. J. Nucl. Med. Mol. Imaging* **2017**, *44*, 2150–2151. [CrossRef]

10. Laduccella, R.; Albano, D.; Annunziata, S.; Calabrò, D.; Argiroffi, G.; Abenavoli, E.; Linguanti, F.; Vento, A.; Bruno, A.; Alongi, P.; et al. Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications. *Cancers* **2019**, *11*, 1412. [CrossRef]

11. Galldiks, N.; Albert, N.L.; Sommerauer, M.; Grous, A.L.; Ganswindt, U.; Law, I.; Preusser, M.; Le Rhun, E.; Vogelbaum, M.A.; Zadeh, G.; et al. PET Imaging in Patients with Meningioma—Report of the RANO/PET Group. *Neuro-Oncol.* **2017**, *19*, 1576–1587. [CrossRef]

12. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Bouton, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. *BMJ* **2021**, *372*, n71. [CrossRef] [PubMed]
36. Pedersen, S.F.; Sandholt, B.V.; Keller, S.H.; Hansen, A.E.; Clemmensen, A.E.; Sillesen, H.; Huigaard, L.; Ripa, R.S.; Kjær, A. 64 Cu-DOTATATE PET/MRI for Detection of Activated Macrophages in Carotid Atherosclerotic Plaques. *Arter. Thromb. Vasc. Biol.* 2015, 35, 1696–1703. [CrossRef] [PubMed]

37. Dandar, A.; Bold, M.S.; Agac, B.; Kendi, A.T.; Friedman, S.N. Stroke Detection with 3 Different PET Tracers. *Radiol. Case Rep.* 2019, 14, 1447–1451. [CrossRef] [PubMed]

38. Hephzibah, J.; John, J.R.; Oommen, R.; Shanthly, N.; Mathew, D. Ga-68 DOTATATE Positron Emission Tomography-Computed Tomography Imaging in Oncogenic Osteomalacia: Experience from a Tertiary Level Hospital in South India. *Indian J. Nucl. Med.* 2019, 34, 188–193. [CrossRef]

39. Broski, S.M.; Folpe, A.L.; Wenger, D.E. Imaging Features of Phosphaturic Mesenchymal Tumors. *Skelet. Radiol.* 2018, 47, 119–127. [CrossRef]

40. Paquet, M.; Gauthé, M.; Yin, J.Z.; Nataf, V.; Bélissant, O.; Orcel, P.; Roux, C.; Talbot, J.-N.; Monträvers, F. Diagnostic Performance and Impact on Patient Management of 68Ga-DOTA-TOC PET/CT for Detecting Osteomalacia-Associated Tumours. *Europ. J. Pediatrics* 2018, 45, 1710–1720. [CrossRef]

41. Satyaraddi, A.; Cherian, K.E.; Shetty, S.; Kapoor, N.; Jebasingh, F.K.; Cherian, V.M.; Hephzibah, J.; Prabhu, A.J.; Thomas, N.; Paul, T.V. Musculoskeletal Oncogenic Osteomalacia-An Experience from a Single Centre in South India. *J. Orthop.* 2017, 14, 184–188. [CrossRef]

42. Gonzalez, G.; Baudrand, R.; Sepúlveda, M.F.; Vucetich, N.; Guarda, F.J.; Villanueva, P.; Contreras, O.; Villa, A.; Salech, F.; Toró, L.; et al. Tumor-Induced Osteomalacia: Experience from a South American Academic Center. *Osteoporos. Int.* 2017, 28, 2187–2193. [CrossRef] [PubMed]

43. El-Maouche, D.; Sadowski, S.M.; Papadakis, G.Z.; Guthrie, L.; Cottle-Delisle, C.; Merkel, R.; Millo, C.; Chen, C.C.; Kebebew, E.; Collins, M.T. 68Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia. *J. Clin. Endocrinol. Metab.* 2016, 101, 3575–3581. [CrossRef] [PubMed]

44. Bhavani, N.; Assirvatham, A.R.; Kallur, K.; Menon, A.S.; Pavithran, P.V.; Nair, V.; Vasukutty, J.R.; Menon, U.; Kumar, H. Utility of Gallium-68 DOTANOC PET/CT in the Localization of Tumour-Induced Osteomalacia. *Clin. Nucl. Med.* 2015, 40, 134–140. [CrossRef] [PubMed]

45. Zhang, J.; Zhu, Z.; Zhong, D.; Dang, Y.; Xing, H.; Du, Y.; Jing, H.; Qiao, Z.; Xing, X.; Zhuang, H.; et al. 68Ga DOTATATE PET/CT Is an Accurate Imaging Modality in the Detection of Culprit Tumors Causing Osteomalacia. *Clin. Nucl. Med.* 2015, 40, 642–646. [CrossRef] [PubMed]

46. Agrawal, K.; Bhadada, S.; Mittal, B.R.; Shukla, J.; Sood, A.; Bhattacharya, A.; Bhansali, A. Comparison of 18F-FDG and 68Ga DOTATATE PET/CT in Localization of Tumor Causing Oncogenic Osteomalacia. *Clin. Nucl. Med.* 2015, 40, e6–e10. [CrossRef] [PubMed]

47. Jadhav, S.; Kasaliwal, R.; Lele, V.; Rangarajan, V.; Chandra, P.; Shah, H.; Malhotra, G.; Jagtap, V.S.; Budyal, S.; Lila, A.R.; et al. Functional Imaging in Primary Tumour-Induced Osteomalacia: Relative Performance of FDG PET/CT vs. Somatostatin Receptor-Based Functional Scans: A Series of Nine Patients. *Clin. Endocrinol.* 2014, 81, 31–37. [CrossRef]

48. Clifton-Bligh, R.; Hofman, M.S.; Duncan, E.; Sim, I.-W.; Darnell, D.; Clarkson, A.; Wong, T.; Walsh, J.; Gill, A.J.; Ebeling, P.R.; et al. Improving Diagnosis of Tumor-Induced Osteomalacia with Gallium-68 DOTANOC PET/CT. *J. Clin. Endocrinol. Metab.* 2013, 98, 687–694. [CrossRef]

49. Singh, D.; Chopra, A.; Ravina, M.; Kongara, S.; Bhatia, E.; Kumar, N.; Gupta, S.; Yadav, S.; Dadagbha, P.; Yadav, R.; et al. Oncogenic Osteomalacia: Role of Ga-68 DOTANOC PET/CT Scan in Identifying the Culprit Lesion and Its Management. *Br. J. Radiol.* 2017, 90, 20160811. [CrossRef]

50. Then, C.; Asbach, E.; Bartsch, H.; Thon, N.; Betz, C.; Reincke, M.; Schmidmaier, R. Fibroblast Growth Factor 23-Producing Phosphaturic Mesenchymal Tumor with Extraordinary Morphology Causing Oncogenic Osteomalacia. *Medicina* 2020, 56, 34. [CrossRef]

51. Kumar, S.; Diamond, T. Lessons Learnt from Delayed Diagnosis of FGF-23-Producing Tumour-Induced Osteomalacia and Post-Operative Hungry Bone Syndrome. *Bone Rep.* 2020, 12, 100276. [CrossRef]

52. Kaur, T.; Rush, E.T.; Bhattacharya, R.K. Phosphaturic Mesenchymal Heel Tumor Presenting with Tumor-Induced Osteomalacia. *AACN Clin. Case Rep.* 2019, 5, e138–e141. [CrossRef] [PubMed]

53. Jia, C.; Shao, F.; Yang, M.; Qin, C.; Lan, X. Giant Cell Tumor of Tendon Sheath Revealed on 68Ga-DOTA-TATE PET/CT in a Patient with Suspicious Tumor-Induced Osteomalacia. *Clin. Nucl. Med.* 2019, 44, 496–498. [CrossRef] [PubMed]

54. Araujo, C.S.R.; Seguro, L.P.C.; Duarte, P.S.; Buchpiguel, C.; Pereira, R.M.R. Intramastoid Phosphaturic Mesenchymal Tumor Causing Hypophosphatemic Osteomalacia Detected on 68Ga-DOTANOC PET/CT But Not on 99mTc-Sestamibi and 18F-FDG Scans. *Nucl. Med. Mol. Imaging* 2019, 53, 436–441. [CrossRef] [PubMed]

55. He, Q.; Xu, Z.; Zhang, B.; Hu, W.; Zhang, X. Tumor-Induced Osteomalacia Caused by a Parotid Basal Cell Adenoma Detected by 68Ga-DOTANOC PET/CT. *Clin. Nucl. Med.* 2018, 43, e198–e199. [CrossRef] [PubMed]

56. Ha, S.; Park, S.; Kim, H.; Go, H.; Lee, S.H.; Choi, J.Y.; Hong, J.Y.; Ryu, J.-S. Successful Localization Using 68Ga-DOTATOC PET/CT of a Phosphaturic Mesenchymal Tumor Causing Osteomalacia in a Patient with Concurrent Follicular Lymphoma. *Nucl. Med. Mol. Imaging* 2018, 52, 462–467. [CrossRef] [PubMed]

57. Ding, J.; Wang, L.; Zhang, S.; Li, F.; Huo, L. Recurrent/Residual Intracranial Phosphaturic Mesenchymal Tumor Revealed on 68Ga-DOTATATE PET/CT. *Clin. Nucl. Med.* 2018, 43, 674–675. [CrossRef]
58. Kawai, S.; Ariyasu, H.; Furukawa, Y.; Yamamoto, R.; Uraki, S.; Takeshima, K.; Wargayama, K.; Nakamoto, Y.; Akamizu, T. Effective Localization in Tumor-Induced Osteomalacia Using 68Ga-DOTATOC-PET/CT, Venous Sampling and 3T-MRI. Endocrinol. Diabetes Metab. Case Rep. 2017, 2017. [CrossRef]

59. Chanuky, G.V.; Mengade, M.; Goud, J.; Rao, I.S.; Jain, A. Tumor-Induced Osteomalacia: A Sherlock Holmes Approach to Diagnosis and Management. Ann. Maxillofac. Surg. 2017, 7, 143–147. [CrossRef]

60. Maybody, M.; Grewal, R.K.; Healey, J.H.; Antonescu, C.R.; Fanchon, L.; Hwang, S.; Carrasquillo, J.A.; Kirow, A.; Farooki, A. Ga-68 DOTATOC PET/CT-Guided Biopsy and Cryoablation with Autoradiography of Biopsy Specimen for Treatment of Tumor-Induced Osteomalacia. Cardiovasc. Interv. Radiol. 2016, 39, 1352–1357. [CrossRef]

61. Maehara, J.; Yamashita, K.; Hiwatachi, A.; Togao, O.; Kikuchi, K.; Matsumoto, Y.; Iura, K.; Oda, Y.; Ichino, I.; Nakamoto, Y.; et al. Primary Phosphaturic Mesenchymal Tumour of the Lumbar Spine: Utility of 68Ga-DOTATOC-PET/CT Findings. BJR Case Rep. 2016, 2, 20150497. [CrossRef]

62. Ho, C.L. Ga68-DOTA Peptide PET/CT to Detect Occult Mesenchymal Tumor-Inducing Osteomalacia: A Case Series of Three Patients. Nucl. Med. Mol. Imaging 2015, 49, 231–236. [CrossRef] [PubMed]

63. Naswa, N.; Sharma, P.; Kumar, R.; Malhotra, A.; Bal, C. Successful Localization of Residual Culprit Tumor in a Case of Tumor-Induced Osteomalacia Using 68Ga-DOTANOC PET/CT. Clin. Nucl. Med. 2013, 38, 639–640. [CrossRef] [PubMed]

64. Haeusler, G.; Freilinger, M.; Dominkus, M.; Egerbacher, M.; Dominkus, M.; Schlegel, W.; Raimann, A.; Staudenherz, A. Tumor-Induced Hypophosphatemic Rickets in an Adolescent Boy—Clinical Presentation, Diagnosis, and Histological Findings in Growth Plate and Muscle Tissue. J. Clin. Endocrinol. Metab. 2010, 95, 4511–4517. [CrossRef]

65. Von Falck, C.; Rodt, T.; Rosenthal, H.; Langer, F.; Goessling, T.; Knapp, W.H.; Galanski, M. 68Ga-DOTATOC PET/CT for the Detection of a Mesenchymal Tumor Causing Oncogenic Osteomalacia. Eur. J. Pediatrics 2008, 35, 1034. [CrossRef]

66. Hesse, E.; Moessinger, E.; Rosenthal, H.; Laenger, F.; Brabant, G.; Petrich, T.; Gratz, K.F.; Bastian, L. Oncogenic Osteomalacia: Exact Localization in Tumor-Induced Osteomalacia Using 68Ga-DOTANOC-PET/CT Scanning in the Evaluation of Patients with Multiple Myeloma. Clin. Nucl. Med. 2019, 44, e57–e59. [CrossRef]

67. Gronkiewicz, Z.; Kukwa, W.; Krollicki, L.; Cyran-Chlebicka, A.; Pawlak, D.; Stankiewicz, C.; Krzeski, A.; Górecka, B.; Wolosz, D.; Kunikowska, J. 68Ga-DOTATATE PET in Juvenile Angiofibroma. Futur. Oncol. 2016, 12, 1483–1491. [CrossRef] [PubMed]

68. Mahajan, S.; Bodei, L.; Castellanos, S.H.; Grewal, R.K. Enchondroma of Tibia as Potential False-positive Finding on 68Ga-DOTANOC PET/CT Scan. Clin. Nucl. Med. 2019, 44, e57–e59. [CrossRef]

69. Vertenten, B.; Goethals, L.; De Geeter, F. 68Ga DOTATATE Uptake in Hemangioma Simulating Metastasis on PET Imaging. J. Belg. Soc. Radiol. 2019, 103, 38. [CrossRef]

70. Liu, H.; Zhang, W.; Chen, Y. Incidental 68Ga-DOTATATE Uptake in Uterine Leiomyoma. Endocrine 2020, 68, 233–234. [CrossRef]

71. Sommezoglu, K.; Vatankulu, B.; Elverdi, T.; Akayel, R.; Erkan, M.E.; Halac, M.; Oacak, M.; Demirci, E.; Aydin, Y. The Role of 68Ga-DOTA-TATE PET/CT Scanning in the Evaluation of Patients with Multiple Myeloma. Nucl. Med. Commun. 2017, 38, 76–83. [CrossRef]

72. Sharma, P.; Dhull, V.S.; Kc, S.S.; Bal, C.; Malhotra, A.; Kumar, R. 68Ga-DOTANOC Somatostatin Receptor PET-CT Imaging in Multiple Myeloma. Clin. Nucl. Med. 2014, 39, 374–375. [CrossRef] [PubMed]

73. Long, Y.; Shao, F.; Lan, X. Mediastinal Epithelioid Hemangioendothelioma Revealed on 68Ga-DOTATATE PET/CT. Clin. Nucl. Med. 2020, 45, 414–416. [CrossRef] [PubMed]

74. Derlin, T.; Huerpe, K.; Soudbah, B. 68Ga-DOTA-TATE PET/CT for Molecular Imaging of Somatostatin Receptor Expression in Metastasizing Epithelioid Hemangioendothelioma. Clin. Nucl. Med. 2017, 42, e478–e479. [CrossRef]

75. Vamadevan, S.; Le, K.; Shen, L.; Loh, H.; Mansberg, R. 68Ga-DOTATATE Uptake in Solitary Pancreatic Metastasis from Clear Cell Renal Cancer. Clin. Nucl. Med. 2017, 42, 700–701. [CrossRef] [PubMed]

76. Vamadevan, S.; Le, K.; Shen, L.; Stevanovic, A.; Loh, H.; Mansberg, R. 68Ga-DOTATATE Uptake in a Soft Tissue Metastasis from Clear Cell Renal Cell Cancer. Clin. Nucl. Med. 2018, 43, 44–45. [CrossRef]

77. Höög, A.; Kjellman, M.; Mattsson, P.; Juulh, C.C.; Shabo, I. Somatostatin Receptor Expression in Renal Cell Carcinoma—A New Front in the Diagnostics and Treatment of Renal Cell Carcinoma. Clin. Genitourin. Cancer 2018, 16, e517–e520. [CrossRef] [PubMed]

78. Braat, A.J.A.T.; Goldschmeding, R.; Brosens, L.A.A.; Vriens, M.R.; de Keizer, B. Gastrointestinal Stromal Tumour Detection with Somatostatin Receptor Imaging. Lancet Oncol. 2017, 18, e185. [CrossRef]

79. Freemeyer, M.; Schulz, S.; Knösel, T.; Settmacher, U. Imaging of Somatostatin Receptor Subtype 2 in Advanced Hepatocellular Carcinoma by 68Ga-DOTATOC PET. Nukl.-Nucl. 2009, 48, N17–N18. [CrossRef]

80. Shamim, S.A.; Tripathy, S.; Bartog, S.; Barwald, A.; Prakash, S. Isolated Pancreatic Metastasis from Choroidal Melanoma after 10 Years of Neureulamation Mimicking Neuroendocrine Tumor on 68Ga-DOTANOC PET/CT. Clin. Nucl. Med. 2020, 46, e21–e22. [CrossRef]

81. Qin, C.; Shao, F.; Lan, X. Diffuse Increased 68Ga-DOTATATE but Unimpressive 18F-FDG Osseous Activity in a Patient with Rapid-Progressing Synchronous Multifocal Osteosarcoma. Clin. Nucl. Med. 2020, 45, 824–826. [CrossRef]

82. Savelli, G.; Muni, A. Somatostatin Receptors in an Anaplastic Oligodendroglioma Relapse Evidenced By 68Ga DOTANOC PET/CT. Clin. Nucl. Med. 2015, 40, e363–e365. [CrossRef] [PubMed]
83. Dejaco, C.; Ramiro, S.; Duffner, C.; Besson, F.L.; Bley, T.A.; Blockmans, D.; Brouwer, E.; Cimmino, M.A.; Clark, E.; Dasgupta, B.; et al. EULAR Recommendations for the Use of Imaging in Large Vessel Vasculitis in Clinical Practice. *Ann. Rheum. Dis.* 2018, 77, 636–643. [CrossRef] [PubMed]

84. Birnie, D.H.; Sauer, W.H.; Bogun, F.; Cooper, J.M.; Culver, D.A.; Duvernoy, C.S.; Judson, M.A.; Kron, J.; Mehta, D.; Nielsen, J.C.; et al. HRS Expert Consensus Statement on the Diagnosis and Management of Arrhythmias Associated with Cardiac Sarcoidosis. *Heart Rhythm* 2014, 11, 1304–1323. [CrossRef]

85. Folpe, A.L.; Fanburg-Smith, J.C.; Billings, S.D.; Bisceglia, M.; Bertoni, F.; Cho, J.Y.; Econis, M.J.; Inwards, C.Y.; de Beur, S.M.J.; Mentzel, T.; et al. Most Osteomalacia-Associated Mesenchymal Tumors Are a Single Histopathologic Entity. *Am. J. Surg. Pathol.* 2004, 28, 1–30. [CrossRef] [PubMed]

86. de Beur, S.M.J.; Streeten, E.A.; Civelek, A.C.; McCarthy, E.F.; Uribe, L.; Marx, S.J.; Onobrakpeya, O.; Raisz, L.G.; Watts, N.B.; Sharon, M.; et al. Localisation of Mesenchymal Tumours by Somatostatin Receptor Imaging. *Lancet* 2002, 359, 761–763. [CrossRef]

87. Dahir, K.; Zanchetta, M.B.; Stanciu, I.; Robinson, C.; Lee, J.Y.; Dhaliwal, R.; Charles, J.; Civitelli, R.; Roberts, M.S.; Krolczyk, S.; et al. Diagnosis and Management of Tumor-Induced Osteomalacia: Perspectives from Clinical Experience. *J. Endocr. Soc.* 2021, 5, bvab099. [CrossRef]

88. van de Donk, N.W.C.J.; Pawlyn, C.; Yong, K.L. Multiple Myeloma. *Lancet* 2021, 397, 410–427. [CrossRef]

89. Stacchiotti, S.; Miah, A.; Frezza, A.; Messiou, C.; Morosi, C.; Caraceni, A.; Antonescu, C.; Bajpai, J.; Baldini, E.; Bauer, S.; et al. Epithelioid Hemangioendothelioma, an Ultra-Rare Cancer: A Consensus Paper from the Community of Experts. *ESMO Open* 2021, 6, 100170. [CrossRef]